Literature DB >> 24628584

Topical photodynamic therapy using different porphyrin precursors leads to differences in vascular photosensitization and vascular damage in normal mouse skin.

Tom A Middelburg1, Hannah C de Vijlder, Henriette S de Bruijn, Angélique van der Ploeg-van den Heuvel, H A Martino Neumann, Ellen R M de Haas, Dominic J Robinson.   

Abstract

Different distributions of hexyl aminolevulinate (HAL), aminolevulinic acid (ALA) and methyl aminolevulinate (MAL) in the superficial vasculature are not well studied but they are hypothesized to play an important role in topical photodynamic therapy (PDT). The colocalization of fluorescent CD31 and protoporphyrin IX (PpIX) was calculated using confocal microscopy of mouse skin sections to investigate the vascular distribution after topical application. Vascular damage leads to disruption of the normal endothelial adherens junction complex, of which CD144 is an integral component. Therefore, normal CD31 combined with loss of normal fluorescent CD144 staining was visually scored to assess vascular damage. Both the vascular PpIX concentration and the vascular damage were highest for HAL, then ALA and then MAL. Vascular damage in MAL was not different from normal contralateral control skin. This pattern is consistent with literature data on vasoconstriction after PDT, and with the hypothesis that the vasculature plays a role in light fractionation that increases efficacy for HAL and ALA-PDT but not for MAL. These findings indicate that endothelial cells of superficial blood vessels synthesize biologically relevant PpIX concentrations, leading to vascular damage. Such vascular effects are expected to influence the oxygenation of tissue after PDT which can be important for treatment efficacy.
© 2014 The American Society of Photobiology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24628584     DOI: 10.1111/php.12271

Source DB:  PubMed          Journal:  Photochem Photobiol        ISSN: 0031-8655            Impact factor:   3.421


  5 in total

1.  In vivo evaluation of battery-operated light-emitting diode-based photodynamic therapy efficacy using tumor volume and biomarker expression as endpoints.

Authors:  Srivalleesha Mallidi; Zhiming Mai; Imran Rizvi; Joshua Hempstead; Stephen Arnason; Jonathan Celli; Tayyaba Hasan
Journal:  J Biomed Opt       Date:  2015-04       Impact factor: 3.170

2.  Vascular alterations after photodynamic therapy mediated by 5-aminolevulinic acid in oral leukoplakia.

Authors:  Flávia Cristina Perillo Rosin; Ana Rita Ribeiro Barcessat; Giuliana Gadoni Giovanni Borges; Luciana Gonçalves Valente Ferreira; Luciana Corrêa
Journal:  Lasers Med Sci       Date:  2016-12-21       Impact factor: 3.161

3.  Light Fractionation Significantly Increases the Efficacy of Photodynamic Therapy Using BF-200 ALA in Normal Mouse Skin.

Authors:  Henriëtte S de Bruijn; Sander Brooks; Angélique van der Ploeg-van den Heuvel; Timo L M Ten Hagen; Ellen R M de Haas; Dominic J Robinson
Journal:  PLoS One       Date:  2016-02-12       Impact factor: 3.240

Review 4.  A review and outlook in the treatment of osteosarcoma and other deep tumors with photodynamic therapy: from basic to deep.

Authors:  Wei Yu; Jian Zhu; Yitian Wang; Junjie Wang; Weijing Fang; Kaishun Xia; Jianlin Shao; Minzu Wu; Bing Liu; Chengzhen Liang; Chengyi Ye; Huimin Tao
Journal:  Oncotarget       Date:  2017-06-13

5.  Comparing desferrioxamine and light fractionation enhancement of ALA-PpIX photodynamic therapy in skin cancer.

Authors:  Ana Luiza Ribeiro de Souza; Kayla Marra; Jason Gunn; Kimberley S Samkoe; Stephen Chad Kanick; Scott C Davis; M Shane Chapman; Edward V Maytin; Tayyaba Hasan; Brian W Pogue
Journal:  Br J Cancer       Date:  2016-08-30       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.